Dr Reddy Laboratories
-
{
- All
- News
-
India To Get First Dengue Vaccine In 2027: What Is QDENGA?
The arrival of QDENGA could add another layer to India's dengue prevention strategy. However, vaccination is expected to complement rather than replace existing public-health measures.
-
Nestle India And Dr Reddy's Laboratories Form Joint Venture Company
The partnership was made to combine the established reputed range of nutritional products of Nestlé Health Science with the nutraceuticals portfolios of Dr. Reddy’s Labs.
-
Dr Reddy's Inks Agreement With Takeda For Patented Peptic Disorder Drug Sale
Vonoprazan is an active potassium competitive acid blocker, used to treat reflux esophagitis.
-
Dr. Reddy's Laboratories Q4 Results: Profit Surges 36%, Beats Estimates
The bottom line of the pharmaceutical company in the fourth quarter stood at Rs 1,310 crore, a jump of 36.4% from the year-ago period.
-
Dr Reddy's Q4 Net Profit Jumps 3-Fold To Rs 337.6 Crore
Dr Reddy's Laboratories had posted a net profit after taxes and shares of associates of Rs 122.6 crore for the corresponding period of the previous fiscal.
-
Dr Reddy's Q4 Net Profit Jumps 3-Fold To Rs 337.6 Crore
Dr Reddy's Laboratories had posted a net profit after taxes and shares of associates of Rs 122.6 crore for the corresponding period of the previous fiscal.
-
Dr Reddy's Second-Quarter Profit Jumps Nearly 70% To 518 Crore Rupees
Dr Reddy's Laboratories revenue in the global generics segment from emerging markets surged 36 per cent to Rs 749 crore.
-
Dr Reddy's Launches Generic Paricalcitol Capsules in US Market
The company had launched Paricalcitol capsules in the US market in strengths of 1 mcg, 2 mcg and 4 mcg on June 24 after getting approval from the United States Food and Drug Administration (USFDA), Dr Reddy's said in a statement.
-
Dr Reddy's Lab Net Profit Declines 28% To Rs 553.5 Crore In March Quarter
Dr Reddy's Lab Q4 FY21 Results: Dr Reddy's Laboratories announced its January-March quarter results, reporting a 27.5 per cent decline in net profit year-on-year at Rs 553.5 crore.
-
Dr Reddy's Laboratories Gets FDA Approval, Launches Drug In US Market
Dr Reddy's Laboratories on Wednesday said it has launched a vasopressin injection, which is used to control frequent urination, increased thirst, and loss of water caused by diabetes, in the American market.
-
Local Production May Bring Down Sputnik V Vaccine Prices: Dr Reddy's
The pricing of the Sputnik V COVID-19 vaccine, currently capped at Rs 995 per dose, is expected to come down once local manufacturing of the vaccine begins, according to a company spokesperson from Dr Reddy's Laboratories.
-
Dr Reddy's Lab Net Profit Declines 28% To Rs 553.5 Crore In March Quarter
Dr Reddy's Lab Q4 FY21 Results: Dr Reddy's Laboratories announced its January-March quarter results, reporting a 27.5 per cent decline in net profit year-on-year at Rs 553.5 crore.
-
Dr. Reddy’s Divests Three Brands To Focus On Profitability
The Hyderabad-based drugmaker said it couldn’t scale up the business of these products.
-
Dr Reddy's Second-Quarter Profit Jumps Nearly 70% To 518 Crore Rupees
Dr Reddy's Laboratories revenue in the global generics segment from emerging markets surged 36 per cent to Rs 749 crore.
-
Q4 Results: Dr. Reddy’s Profit Declines For Fourth Straight Quarter
Dr. Reddy’s Laboratories’ net profit fell 3.3 percent to Rs 302.2 crore during the January-March period.
-
India To Get First Dengue Vaccine In 2027: What Is QDENGA?
The arrival of QDENGA could add another layer to India's dengue prevention strategy. However, vaccination is expected to complement rather than replace existing public-health measures.
-
Nestle India And Dr Reddy's Laboratories Form Joint Venture Company
The partnership was made to combine the established reputed range of nutritional products of Nestlé Health Science with the nutraceuticals portfolios of Dr. Reddy’s Labs.
-
Dr Reddy's Inks Agreement With Takeda For Patented Peptic Disorder Drug Sale
Vonoprazan is an active potassium competitive acid blocker, used to treat reflux esophagitis.
-
Dr. Reddy's Laboratories Q4 Results: Profit Surges 36%, Beats Estimates
The bottom line of the pharmaceutical company in the fourth quarter stood at Rs 1,310 crore, a jump of 36.4% from the year-ago period.
-
Dr Reddy's Q4 Net Profit Jumps 3-Fold To Rs 337.6 Crore
Dr Reddy's Laboratories had posted a net profit after taxes and shares of associates of Rs 122.6 crore for the corresponding period of the previous fiscal.
-
Dr Reddy's Q4 Net Profit Jumps 3-Fold To Rs 337.6 Crore
Dr Reddy's Laboratories had posted a net profit after taxes and shares of associates of Rs 122.6 crore for the corresponding period of the previous fiscal.
-
Dr Reddy's Second-Quarter Profit Jumps Nearly 70% To 518 Crore Rupees
Dr Reddy's Laboratories revenue in the global generics segment from emerging markets surged 36 per cent to Rs 749 crore.
-
Dr Reddy's Launches Generic Paricalcitol Capsules in US Market
The company had launched Paricalcitol capsules in the US market in strengths of 1 mcg, 2 mcg and 4 mcg on June 24 after getting approval from the United States Food and Drug Administration (USFDA), Dr Reddy's said in a statement.
-
Dr Reddy's Lab Net Profit Declines 28% To Rs 553.5 Crore In March Quarter
Dr Reddy's Lab Q4 FY21 Results: Dr Reddy's Laboratories announced its January-March quarter results, reporting a 27.5 per cent decline in net profit year-on-year at Rs 553.5 crore.
-
Dr Reddy's Laboratories Gets FDA Approval, Launches Drug In US Market
Dr Reddy's Laboratories on Wednesday said it has launched a vasopressin injection, which is used to control frequent urination, increased thirst, and loss of water caused by diabetes, in the American market.
-
Local Production May Bring Down Sputnik V Vaccine Prices: Dr Reddy's
The pricing of the Sputnik V COVID-19 vaccine, currently capped at Rs 995 per dose, is expected to come down once local manufacturing of the vaccine begins, according to a company spokesperson from Dr Reddy's Laboratories.
-
Dr Reddy's Lab Net Profit Declines 28% To Rs 553.5 Crore In March Quarter
Dr Reddy's Lab Q4 FY21 Results: Dr Reddy's Laboratories announced its January-March quarter results, reporting a 27.5 per cent decline in net profit year-on-year at Rs 553.5 crore.
-
Dr. Reddy’s Divests Three Brands To Focus On Profitability
The Hyderabad-based drugmaker said it couldn’t scale up the business of these products.
-
Dr Reddy's Second-Quarter Profit Jumps Nearly 70% To 518 Crore Rupees
Dr Reddy's Laboratories revenue in the global generics segment from emerging markets surged 36 per cent to Rs 749 crore.
-
Q4 Results: Dr. Reddy’s Profit Declines For Fourth Straight Quarter
Dr. Reddy’s Laboratories’ net profit fell 3.3 percent to Rs 302.2 crore during the January-March period.
